Intracoronary Versus Intravenous Abciximab Delivery

In STEMI patients, the intracoronary route was associated with greater improvements in infarct size and microvascular perfusion.

During primary percutaneous coronary intervention for ST-segment-elevation MI, adjunctive administration of intravenous (IV) abciximab reduces the incidence of subsequent adverse cardiac events. To explore whether delivery of abciximab directly to the site of obstruction might further improve outcomes, investigators randomized 154 patients undergoing PCI for STEMI to receive the bolus dose of abciximab by either an IV or an intracoronary (IC) route.

The primary study endpoint was infarct size as measured by magnetic resonance imaging, which was performed in about 90% of patients at a median of 2 days after PCI. Median infarct size was smaller with IC administration than with IV administration (15% vs. 23% of the left ventricle, P=0.01). Micr…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI